Stroke centers and intravenous tissue plasminogen activators (tPA) are effective management for acute ischemic stroke. This study aimed to analyze stroke center characteristics on the administration of thrombolytic therapy. A national survey of stroke centers in academic medical centers and regional teaching hospitals in Taiwan was conducted. The survey questions included the number of tPA or other thrombolytic therapies, presence of stroke intensive care units and wards, initiation of rehabilitation, and 15 criteria for establishment of stroke centers adopted from the Brain Attack Coalition's recommendation. Factors influencing administration of thrombolytic therapy were analyzed. Intravenous tPA increased from 135 cases in 2004 to 246 cas...
Intravenous recombinant tissue plasminogen activator is a highly effective treatment for acute ische...
INTRODUCTION: In this study, we aimed to discuss the data of patients with acute ischemic stroke wit...
Background and Purpose—Today, treatment of acute stroke consists of tissue-type plasminogen activato...
Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evi...
Objective: To reveal the profile and practice in patients with acute stroke who received intravenous...
Background: This study aims at investigating ischaemic stroke therapy in Germany by using secondary ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Context Intravenous tissue-type plasminogen activator (tPA) therapy using the National Institute of ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Background: This study aims at investigating ischaemic stroke therapy in Germany by using secondary ...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
INTRODUCTION: Acute ischemic stroke is frequently encountered in emergency neurology clinics. Especi...
Background—We sought to determine if intravenous tissue plasminogen activator (IV tPA) use for acute...
BACKGROUND AND PURPOSE: The prospective trials evaluating the safety and efficacy of intravenous tis...
INTRODUCTION: Stroke as a cause of death ranks 3rd in our country as well as in the world. Furthermo...
Intravenous recombinant tissue plasminogen activator is a highly effective treatment for acute ische...
INTRODUCTION: In this study, we aimed to discuss the data of patients with acute ischemic stroke wit...
Background and Purpose—Today, treatment of acute stroke consists of tissue-type plasminogen activato...
Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evi...
Objective: To reveal the profile and practice in patients with acute stroke who received intravenous...
Background: This study aims at investigating ischaemic stroke therapy in Germany by using secondary ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Context Intravenous tissue-type plasminogen activator (tPA) therapy using the National Institute of ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Background: This study aims at investigating ischaemic stroke therapy in Germany by using secondary ...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
INTRODUCTION: Acute ischemic stroke is frequently encountered in emergency neurology clinics. Especi...
Background—We sought to determine if intravenous tissue plasminogen activator (IV tPA) use for acute...
BACKGROUND AND PURPOSE: The prospective trials evaluating the safety and efficacy of intravenous tis...
INTRODUCTION: Stroke as a cause of death ranks 3rd in our country as well as in the world. Furthermo...
Intravenous recombinant tissue plasminogen activator is a highly effective treatment for acute ische...
INTRODUCTION: In this study, we aimed to discuss the data of patients with acute ischemic stroke wit...
Background and Purpose—Today, treatment of acute stroke consists of tissue-type plasminogen activato...